Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 34 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Phase III Chemotherapy with DTIC vs Therapy with the Single Most Active Agent Identified by Clonogenic Assay for Advanced Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				15 to 75								UARIZ-1718H NCI-V84-0058


2.		Phase I/II Chemotherapy with 4'-Deoxydoxorubicin Administered on an Escalating Schedule in Patients with Previously Treated Stage IV Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				under physiologic 60				NCI				MTS-84040 NCI-T84-0235D, T84-0235


3.		Phase I/II Chemotherapy with 4'-Deoxydoxorubicin Hydrochloride in Children with Malignant Solid Tumors (last Modified 11/87)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				under 18				NCI				SJCRH-DXDX1-2 NCI-T84-0439D, T84-0439


4.		Phase I/II Chemotherapy with DxDx in Patients with Refractory Acute Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				no age specified				NCI				AECM-8473 NCI-T84-0352D, T84-0352


5.		Phase I/II Master Protocol Chemotherapy in Patients with Refractory Acute Leukemia and Chronic Myelogenous Leukemia in Blast Crisis --- 4'-Deoxydoxorubicin

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				over 15				NCI				CORN-8402 NCI-T84-0208W, T84-0208

Last Modified: 9/19/2006


6.		Phase II Master Protocol for Evaluation of New Agents for Residual, Recurrent, or Metastatic Primary Liver Cancer --- Acivicin vs 4'-Deoxydoxorubicin

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				no age specified				NCI				EST-2282

Last Modified: 4/26/2007


7.		Phase II Chemotherapy with 4'-Deoxydoxorubicin for Metastatic Renal Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				no age specified				NCI				WSU-C-52883 NCI-T83-1413C, T83-1413


8.		Phase II Chemotherapy with 4'-Deoxydoxorubicin for Metastatic or Recurrent, Unresectable Adenocarcinoma of the Colon or Rectum

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				no age specified				NCI				ICC-84I1 NCI-T84-0232D, T84-0232


9.		Phase II Chemotherapy with 4'-Deoxydoxorubicin for Unresectable or Recurrent non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				physiologic 70 and under				NCI				UMCC-8327 NCI-T84-0210W, T84-0210


10.		Phase II First-Line Chemotherapy with 4'-Deoxydoxorubicin for Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				no age specified				NCI				WSU-C-53984 NCI-T84-0193C, T84-0193

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute